Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cell surface markers in multiple myeloma

G J Ruiz-Argüelles1, J F San Miguel

  • 1Centro de Hematología y Medicina Interna, Puebla, México.

Mayo Clinic Proceedings
|July 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression.

Blood cancer journal·2024
Same author

Self-reported changes in the expanded disability status scale score in patients with multiple sclerosis after autologous stem cell transplants: real-world data from a single center.

Clinical and experimental immunology·2019
Same author

The Latin American experience of allografting patients with severe aplastic anaemia: real-world data on the impact of stem cell source and ATG administration in HLA-identical sibling transplants.

Bone marrow transplantation·2016
Same author

Congenital Acute Megakaryoblastic Leukaemia in Down's Syndrome.

Leukemia & lymphoma·2016
Same author

Are there "Attenuated" Forms of Evans Syndrome?

Hematology (Amsterdam, Netherlands)·2016
Same author

Inverse Probability of Censoring Weighted Analysis to Adjust the Treatment Effect on Overall Survival for Subsequent Therapy: A Case Study in a Clinical Trial in Multiple Myeloma.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2016
Same journal

Thyroid Dysfunction and the Risk of Clinically Relevant Depression: A Longitudinal Cohort Study.

Mayo Clinic proceedings·2026
Same journal

37-Year-Old Woman With Jaundice.

Mayo Clinic proceedings·2026
Same journal

34-Year-Old Woman With An Unidentified Overdose.

Mayo Clinic proceedings·2026
Same journal

Use of Bronchoscopic Cryobiopsy in Evaluating Interstitial Lung Disease: Radiologic Predictors of Diagnostic Yield and Safety.

Mayo Clinic proceedings·2026
Same journal

Advancing Pulmonary Fibrosis Care: Integrating Genomic Insights Into Clinical Practice.

Mayo Clinic proceedings·2026
Same journal

RAAS Inhibition in the ICU: Stop, Continue, or Restart?

Mayo Clinic proceedings·2026
See all related articles

This study details the cell surface markers on normal and multiple myeloma (MM) plasma cells (PCs). Certain antigen expressions on MM cells may indicate prognosis, warranting further investigation.

Area of Science:

  • Hematology
  • Immunology
  • Oncology

Background:

  • Multiple myeloma (MM) is a cancer of plasma cells (PCs).
  • Understanding the immunophenotype of normal and malignant PCs is crucial for diagnosis and treatment.
  • Changes in non-malignant immunoregulatory cells in MM also impact the disease.

Purpose of the Study:

  • To characterize the immunophenotype of normal and myelomatous plasma cells (PCs).
  • To investigate changes in immunoregulatory non-myelomatous cells in multiple myeloma (MM).
  • To explore the prognostic significance of cell surface markers in MM.

Main Methods:

  • Review of cell surface markers (antigens) associated with multiple myeloma.
  • Immunophenotypic characterization using monoclonal antibodies.

Related Experiment Videos

  • Application of flow cytometry or immunocytochemical techniques for cell analysis.

    • Main Results:

    • Normal PCs exhibit heterogeneity, expressing antigens like CD9, CD10, CD13, CD19, CD20, CD33, CD38, and HLA-DR.
    • Myelomatous PCs share some markers (CD38, CD9, CD10, HLA-DR, CD20) but can also express non-B-cell lineage markers (myeloid, T-cell, NK-associated).
    • Expression of certain antigens (e.g., CD20, myelomonocytic antigens) may correlate with a poor prognosis in MM patients.

    Conclusions:

    • The immunophenotype of plasma cells in multiple myeloma is complex and heterogeneous.
    • Specific cell surface markers on plasma cells may hold prognostic value in MM.
    • Further research is needed to fully understand the significance of these markers in MM.